These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10321931)

  • 21. A patient with Paget's disease of bone treated with etidronate disodium.
    Koga K; Kawasaki K; Kohno S; Yamada K; Itoh T; Nonaka K
    Kurume Med J; 1998; 45(4):345-9. PubMed ID: 9914722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate.
    Watts NB; Becker P
    Bone; 1999 Jan; 24(1):65-8. PubMed ID: 9916786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Long-term experience using EHDP (ethylidene-1-hydroxy-1,1-diphosphonate) in the treatment of Paget's disease].
    Sieghart S
    Wien Med Wochenschr; 1986 Nov; 136(21-22):583-5. PubMed ID: 3103338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Etidronic acid therapy in Paget's disease of bone].
    Holz G; Delling G; Ziegler R
    Dtsch Med Wochenschr; 1983 Dec; 108(51-52):1954-8. PubMed ID: 6418505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteomalacia in a patient with Paget's bone disease treated with long-term etidronate.
    Hoppé E; Masson C; Laffitte A; Chappard D; Audran M
    Morphologie; 2012 Aug; 96(313):40-3. PubMed ID: 23022200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Procollagen-III peptide serum levels in Paget's disease of the bone.
    Wilder-Smith CH; Raue F; Holz-Gottswinter G; Ziegler R
    Klin Wochenschr; 1987 Feb; 65(4):174-8. PubMed ID: 3104661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term follow-up of therapy with intermittent etidronate disodium in Paget's disease of bone.
    Altman RD
    Am J Med; 1985 Nov; 79(5):583-90. PubMed ID: 3933343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duration of effect of oral diphosphonate therapy in Paget's disease of bone.
    Gray RE; Yates AJ; Preston CJ; Smith R; Russell RG; Kanis JA
    Q J Med; 1987 Sep; 64(245):755-67. PubMed ID: 2966965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stabilization of hearing loss in Paget's disease with calcitonin and etidronate.
    Lando M; Hoover LA; Finerman G
    Arch Otolaryngol Head Neck Surg; 1988 Aug; 114(8):891-4. PubMed ID: 3134037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of two oral doses of alendronate in the treatment of Paget's disease of bone.
    Adami S; Mian M; Gatti P; Rossini M; Zamberlan N; Bertoldo F; Lo Cascio V
    Bone; 1994; 15(4):415-7. PubMed ID: 7917580
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction and assessment of the response of Paget's disease to bisphosphonate treatment.
    Hosking DJ
    Bone; 1999 May; 24(5 Suppl):69S-71S. PubMed ID: 10321933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paget's disease of bone. Experience with a diphosphonate (disodium etidronate) in treatment.
    Smith R; Russell RG; Bishop MC; Woods CG; Bishop M
    Q J Med; 1973 Apr; 42(166):235-56. PubMed ID: 4206518
    [No Abstract]   [Full Text] [Related]  

  • 33. Bisphosphonates for Paget's disease of bone in adults.
    Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.
    Stuckey BG; Lim EM; Kent GN; Ward LC; Gutteridge DH
    J Bone Miner Res; 2001 Sep; 16(9):1719-23. PubMed ID: 11547843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alternate calcitonin and etidronate disodium therapy for Paget's bone disease.
    Perry HM; Droke DM; Avioli LV
    Arch Intern Med; 1984 May; 144(5):929-33. PubMed ID: 6424594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of Paget's disease of bone with ethane-1 hydroxy-1, 1 diphosphonate at low dosage (author's transl)].
    Alexandre C; Chapuy MC; Bressot C; Vignon E; Arlot M; Mathieu L; Edouard C; Johnston CC; Meunier PJ
    Nouv Presse Med; 1980 Nov; 9(45):3429-33. PubMed ID: 6777752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effective short term treatment of Paget's disease with oral etidronate.
    Preston CJ; Yates AJ; Beneton MN; Russell RG; Gray RE; Smith R; Kanis JA
    Br Med J (Clin Res Ed); 1986 Jan; 292(6513):79-80. PubMed ID: 3080099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of alendronate treatment on the clinical picture and bone turnover markers in chronic idiopathic hyperphosphatasia.
    Demir E; Bereket A; Ozkan B; Topçu M
    J Pediatr Endocrinol Metab; 2000 Feb; 13(2):217-21. PubMed ID: 10711670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biochemical response to combination of disodium etidronate with calcitonin in Paget's disease.
    O'Donoghue DJ; Hosking DJ
    Bone; 1987; 8(4):219-25. PubMed ID: 3128315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paget's disease of bone: benefits of neridonate as a first treatment and in cases of relapse after clodronate.
    Filipponi P; Cristallini S; Policani G; Casciari C; Gregorio F
    Bone; 1998 Dec; 23(6):543-8. PubMed ID: 9855463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.